

bs-5085R**[Primary Antibody]****MVD Rabbit pAb****BioSS**
ANTIBODIES

www.bioss.com.cn


sales@bioss.com.cn

techsupport@bioss.com.cn


400-901-9800

— DATASHEET —

Host: Rabbit Clonality: Polyclonal GeneID: 4597 Target: MVD Immunogen: KLH conjugated synthetic peptide derived from human MVD: 201-300/400. Purification: affinity purified by Protein A Concentration: 1mg/ml Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. Background: The enzyme mevalonate pyrophosphate decarboxylase (MVD) catalyzes the conversion of mevalonate pyrophosphate into isopentenyl pyrophosphate in one of the early steps in cholesterol biosynthesis. It decarboxylates and dehydrates its substrate while hydrolyzing ATP.	Isotype: IgG SWISS: P53602	Applications: WB (1:500-2000) IHC-P (1:100-500) IHC-F (1:100-500) IF (1:100-500) Reactivity: Human, Mouse, Rat (predicted: Rabbit, Cow, Dog, Horse) Predicted MW.: 43 kDa Subcellular Location: Cytoplasm
---	---	--

— VALIDATION IMAGES —

Sample: H9C2(Rat) Cell Lysate at 30 ug
HepG2(Human) Cell Lysate at 30 ug
Primary: Anti-MVD (bs-5085R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 43 kD
Observed band size: 43 kD



Paraformaldehyde-fixed, paraffin embedded (mouse brain tissue); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (MVD) Polyclonal Antibody, Unconjugated (bs-5085R) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructions and DAB staining.

— SELECTED CITATIONS —

- **[IF=2.629]** Li Yanchu. et al. Effects of a Chlorogenic Acid-Containing Herbal Medicine (LASNB) on Colon Cancer. Evid-Based Compl Alt. 2021;2021:9923467 IHC ;Mouse. 34462643
- **[IF=1.813]** Li Y et al. Study on the Anticancer Effect of an Astragaloside- and Chlorogenic Acid-Containing Herbal Medicine (RLT-03) in Breast Cancer. Evid Based Complement Alternat Med. 2020 Jun 10;2020:1515081. IHC ;Human. 32595723